In vitro data suggest protective roles for vitamins K and D in inflammation. To examine associations between vitamins K and D and inflammation in vivo, the authors used multiple linear regression analyses, adjusted for age, sex, body mass index, triglyceride concentrations, use of aspirin, use of lipid-lowering medication, season, menopausal status, and hormone replacement therapy. Participants were from the Framingham Offspring Study (1997)(1998)(1999)(2000)(2001); n ¼ 1,381; mean age ¼ 59 years; 52% women). Vitamin K status, measured by plasma phylloquinone concentration and phylloquinone intake, was inversely associated with circulating inflammatory markers as a group and with several individual inflammatory biomarkers (p < 0.01). Percentage of undercarboxylated osteocalcin, a functional measure of vitamin K status, was not associated with overall inflammation but was associated with C-reactive protein (p < 0.01). Although plasma 25-hydroxyvitamin D was inversely associated with urinary isoprostane concentration, an indicator of oxidative stress (p < 0.01), overall associations between vitamin D status and inflammation were inconsistent. The observation that high vitamin K status was associated with lower concentrations of inflammatory markers suggests that a possible protective role for vitamin K in inflammation merits further investigation. inflammation; vitamin D; vitamin K Abbreviations: CV, coefficient of variation; SD, standard deviation.
Cardiovascular disease and osteoporosis are major agerelated health concerns that contribute to morbidity and mortality in the elderly (1) . Inflammation is characteristic of these two chronic diseases (2, 3) . Several proinflammatory cytokines, such as interleukin-6, osteoprotegerin, and tumor necrosis factor-a, are implicated in the process of vascular calcification and the regulation of bone remodeling (4, 5) . The reciprocal effect of inflammatory cytokines on vascular and bone tissue may partially explain the simultaneous manifestation of bone loss and vascular calcification (6, 7) .
Vitamins K and D are fat-soluble vitamins that have been implicated in both cardiovascular and bone health, and more recently in the activity of proinflammatory cytokines.
Vitamin K is an established cofactor in the c-carboxylation of vitamin K-dependent proteins. Two vitamin K-dependent proteins, osteocalcin and matrix c-carboxyglutamate (matrixGla) protein, are present in skeletal and vascular tissue, respectively (8) , and a role for vitamin K in cardiovascular and skeletal health has been reported (9, 10) . Vitamin K also is associated with decreased production of proinflammatory cytokines in studies carried out in vitro (11) (12) (13) . With the exception of one small study conducted in patients with chronic kidney disease (14) , studies of the relations between vitamin K and inflammatory cytokines to date have primarily been carried out in vitro (11, 13) .
The importance of vitamin D for optimal calcium homeostasis and bone metabolism is well-recognized (15) , and there is some suggestion of a role for vitamin D in reducing cardiovascular disease risk (16, 17) . Furthermore, in vitro data suggest that the biologically active form of vitamin D (1,25-dihydroxyvitamin D or calcitriol) has several immunomodulatory functions, including suppression of proinflammatory cytokine expression and regulation of immune cell activity (18) . In vivo, vitamin D supplementation has been associated with a reduction in proinflammatory cytokines in patients with osteoporosis (19) and heart failure (20) but not in healthy persons (21) .
We hypothesized that vitamin K and vitamin D status are inversely associated with measures of inflammation in older adults. To test this hypothesis, we examined cross-sectional associations between dietary and biochemical measures of vitamin K status (plasma phylloquinone, serum percentage of undercarboxylated osteocalcin, and phylloquinone intake) and vitamin D status (plasma 25-hydroxyvitamin D and vitamin D intake) and a panel of circulating proinflammatory biomarkers (C-reactive protein, CD40 ligand, P-selectin, osteoprotegerin, tumor necrosis factor-a, tumor necrosis factor receptor-2, intercellular adhesion molecule-1, interleukin-6, monocyte chemoattractant protein, myeloperoxidase, urinary isoprostanes, fibrinogen, and lipoprotein phospholipase A 2 mass and activity) in the Framingham Offspring Study cohort, a community-based sample of men and women.
MATERIALS AND METHODS
The design and selection criteria of the Framingham Offspring Study have been described elsewhere (22) . Every 4-8 years, Offspring participants undergo extensive evaluations that include medical history, medication use, physical examinations, blood biochemical analyses, and assessment of cardiovascular disease risk factors. Participants were excluded from the present investigation, which took place between 1997 and 2001, if they were currently taking steroidal antiinflammatory medication (n ¼ 219) or anticoagulant medication (n ¼ 41), did not have a valid food frequency questionnaire (n ¼ 59), or did not have data on all of the measures of inflammatory markers (n ¼ 271), excluding tumor necrosis factor-a or urinary isoprostanes. Of the 1,850 eligible participants, data on 1,381 persons (669 male, 712 female) were available for analysis.
Self-reported information on alcohol use, dietary intake, and, for women, menopausal status and hormone replacement therapy was routinely collected. Nutrient intakes from foods and supplements, including phylloquinone (vitamin K 1 ) and vitamin D, were assessed using the Willett food frequency questionnaire (23) . Questionnaires were considered invalid and data were excluded from analysis if the participant reported an energy intake of less than 2.51 MJ/ day or more than 16.74 MJ/day (600 kcal/day and 4,000 kcal/day, respectively) or if the participant had left more than 12 items blank on the food frequency questionnaire (n ¼ 59). This study was approved by the institutional review boards at Tufts University and Boston University Medical Center. All participants gave written informed consent.
Fasting (>10 hours) blood samples were collected between 1997 and 1999, and plasma/serum was stored at À80°C until analysis. The measures used for assessment of vitamin status straddled the end of cycle 6 (1995-1998) (n ¼ 694) and the beginning of cycle 7 (1998-2001) (n ¼ 687), because of the award date of the vitamin assay research grant. Vitamin K status was assessed through measures of plasma phylloquinone and serum percentage of undercarboxylated osteocalcin. A high percentage of undercarboxylated osteocalcin is indicative of low vitamin K status in bone. Plasma phylloquinone concentrations were determined using reverse-phase high performance liquid chromatography, as described elsewhere (24) . Low and high control specimens had average values of 0.56 nmol/liter and 3.15 nmol/liter, with coefficients of variation (CVs) of 15.2 percent and 10.9 percent, respectively. Serum total osteocalcin and undercarboxylated osteocalcin were measured by radioimmunoassay, using the method of Gundberg et al. (25) . Percentage of undercarboxylated osteocalcin, a functional marker of vitamin K status, was determined by the amount of osteocalcin that did not bind to hydroxyapatite in vitro. Since this binding varied with the amount of total osteocalcin in the sample, undercarboxylated osteocalcin was expressed as a percentage of total osteocalcin (26) . The CVs for the three control serum samples, which had average total osteocalcin results of 3.4 lg/liter, 7.1 lg/liter, and 11.9 lg/liter, were 22.3 percent, 12.8 percent, and 7.8 percent, respectively. Vitamin D status was estimated by measuring plasma 25-hydroxyvitamin D concentration, the standard measure of vitamin D status (which reflects both sun-induced synthesis in the skin and dietary intake), using a radioimmunoassay (DiaSorin Inc., Stillwater, Minnesota). The CVs for the control values of 36 nmol/liter and 137 nmol/liter were 8.5 percent and 13.2 percent, respectively.
The following inflammatory biomarkers were measured in duplicate from samples taken during the seventh examination cycle (1998-2001), using commercially available enzyme-linked immunoassay kits: plasma CD40 ligand (Bender MedSystems, Inc., Burlingame, California; intraassay CV ¼ 5.2 percent (standard deviation (SD), 6.4)), plasma P-selectin (R&D Systems, Inc., Minneapolis, Minnesota; intraassay CV ¼ 3.2 percent (SD, 2.4)), plasma osteoprotegerin (BioMedica Gesellschaft mbH, Vienna, Austria; distributed by ALPCO Diagnostics, Salem, New Hampshire; intraassay CV ¼ 3.7 percent (SD, 2.9)), plasma tumor necrosis factor-a (R&D Systems; intraassay CV ¼ 8.8 percent), plasma tumor necrosis factor receptor-2 (R&D systems; intraassay CV ¼ 2.3 percent (SD, 1.6)), serum soluble intercellular adhesion molecule-1 (R&D systems; intraassay CV ¼ 3.9 percent (SD, 2.9)), serum interleukin-6 (R&D Systems; intraassay CV ¼ 3.1 percent (SD, 2.2)), serum monocyte chemoattractant protein-1 (R&D systems; intraassay CV ¼ 3.8 percent (SD, 3.3)), serum myeloperoxidase (Oxis International, Inc., Foster City, California; intraassay CV ¼ 3.2 percent (SD, 2.7)), and urinary isoprostanes indexed to urinary creatinine (27) (Cayman Chemical, Inc., Ann Arbor, Michigan; intraassay CV ¼ 9.6 percent (SD, 6.8)). Single determinants of serum C-reactive protein were made using a high-sensitivity assay (Dade Behring Inc., Deerfield, Illinois; intraassay CV ¼ 3.2 percent) (28) . Fibrinogen was measured in duplicate using the clot-time method of Claus (29) with Diagnostica Stago reagents (Diagnostica Stago, Inc., Parsippany, New Jersey; intraassay CV ¼ 1.1 percent (SD, 1.1)). Lipoprotein phospholipase A 2 mass and activity were measured by diaDexus, Inc. (San Francisco, California) and GlaxoSmithKline (Philadelphia, Pennsylvania), respectively (intraassay CVs of 4.3 percent (SD, 7.8) and 4.3 percent (SD, 7.8), respectively).
Statistical analyses
To improve the symmetry of skewed distributions, data on all of the inflammatory markers and markers of vitamin K status, including intake, were logarithmically transformed for analysis. We generated an inflammation index to create an indicator of overall inflammation by summing the normalized deviates of the individual markers of inflammation (30) . The inflammation index was correlated with the log of each individual marker (Pearson r ¼ 0.12-0.62; all p's < 0.01). In multivariable-adjusted linear regression models, the measures of vitamin K status and vitamin D status were used as continuous regressor variables (each in separate models) and the index or biomarkers of inflammation were used as the dependent variables (one at a time). Although we assessed associations of measures of vitamin K and D status with plasma tumor necrosis factor-a and urinary isoprostanes, these two inflammatory markers were not included in the inflammation index because the numbers of persons with these measures (n ¼ 992 and n ¼ 1,087, respectively) were lower than the numbers with the other measures (specimen collection for their assays occurred later in the examination cycle); including them in the inflammation index would have reduced the sample size for the inflammation index models.
Additional covariates, which were taken from the same examination cycle (cycle 6 or 7) as the measures of vitamin K and D status, included triglycerides, body mass index (weight (kg)/height (m)
2 ), use of aspirin, use of lipidlowering medication, menopausal status, and hormone replacement therapy. The covariates selected were those that were determined to be statistically significantly correlated with the corresponding biochemical measures of vitamin status (M. K. S., unpublished data). Since seasonal differences in vitamin D status and percentage of undercarboxylated osteocalcin have been reported (31, 32) , we included season as a covariate in the models to assess associations between vitamin D status and percentage of undercarboxylated osteocalcin and the markers of inflammation. We chose to report changes in inflammation associated with a twofold increase in plasma phylloquinone level, phylloquinone intake, serum percentage of undercarboxylated osteocalcin, and plasma 25-hydroxyvitamin D level, since these increments of change were deemed plausible on the basis of mean values and ranges for the vitamin status measures. Our primary analyses focused on the associations between measures of vitamin status and the inflammation index. Associations between measures of vitamin status and individual markers of inflammation were considered in secondary analyses. In subsequent analyses, we excluded persons with prevalent cardiovascular disease at examination 7. A p value of 0.01 or less was considered statistically significant. All analyses were performed using SAS 9.1 (SAS Institute, Inc., Cary, North Carolina).
We tested for effect modification by sex and age for each inflammatory marker by entering product terms (age 3 vitamin status or sex 3 vitamin status) into the multiple linear regression models. We also checked effect modification by examination cycle, because the measures of vitamin K status and vitamin D status were not consistently taken from the same examination as the measures of inflammation. To reduce the likelihood of type 1 error, we used a Bonferroni adjustment and considered interactions to be significant if the p value was less than 0.003. None of the interaction terms we tested were significant at this level, and therefore they were not included in the final statistical models.
RESULTS
Study participants' characteristics were typical of those of a community-based cohort (table 1) . Participants were middle-aged to elderly (mean age ¼ 59 years; range, 35-89 years), and 51.6 percent were female. The prevalence of reported use of osteoporosis medication was 6.2 percent, and that of use of lipid-lowering medication was 20.5 percent. Mean concentrations of plasma phylloquinone, plasma 25-hydroxyvitamin D, and serum percentage of undercarboxylated osteocalcin and their standard deviations were within previously reported reference ranges for these assays (26, 33, 34) .
Vitamin K status, as measured by plasma phylloquinone concentration and phylloquinone intake, was significantly inversely associated with the overall inflammation index, which represented the sum of the normalized deviates of the individual markers (table 2). When we reran the statistical analyses with inclusion of tumor necrosis factor-a and urinary isoprostanes in the summary statistic, the associations were similar in direction and significance, although the association between vitamin K intake and the summary statistic was attenuated slightly (p ¼ 0.002) because of the smaller sample size (data not shown).
Secondary analyses of the individual markers demonstrated significant (p < 0.01) associations with five of the 14 markers (table 2) . In multivariable-adjusted analyses, a twofold higher plasma phylloquinone concentration was associated with a 15 percent lower CD40 ligand concentration, a 3 percent lower intracellular adhesion molecule-1 concentration, an 8 percent lower interleukin-6 concentration, a 4 percent lower serum osteoprotegerin concentration, and a 4 percent lower tumor necrosis factor receptor-2 concentration. Usual dietary phylloquinone intake was also significantly (p 0.01) inversely associated with concentrations of C-reactive protein, fibrinogen, interleukin-6, myeloperoxidase, osteoprotegerin, and urinary isoprostane and with lipoprotein phospholipase A 2 mass (table 2). Percentage of undercarboxylated osteocalcin and plasma 25-hydroxyvitamin D were not significantly associated with overall inflammation, as indicated by the inflammation index (tables 2 and 3). However, plasma 25-hydroxyvitamin D was significantly inversely associated with urinary isoprostane concentration (p < 0.01), a measure of oxidative stress that was not included in the inflammation index.
Exclusion of persons with prevalent cardiovascular disease did not change associations between plasma phylloquinone and markers of inflammation. The association between percentage of undercarboxylated osteocalcin and C-reactive protein was attenuated (p ¼ 0.02). However, in these same persons, the inverse association between phylloquinone intake and C-reactive protein reached statistical significance (p ¼ 0.009), and plasma 25-hydroxyvitamin D was significantly inversely associated with interleukin 6 (p ¼ 0.009) (data not shown).
DISCUSSION
In our community-based sample, there was an inverse association between vitamin K status, as measured by plasma phylloquinone level and phylloquinone intake, and overall circulating markers of inflammation. In the same cohort, vitamin D status, as measured by plasma 25-hydroxyvitamin D level, was not consistently associated with systemic inflammatory markers.
Our findings are in general agreement with those from in vitro studies that found a decrease in the production of inflammatory markers, including interleukin-6, by human macrophage and fibroblast cells with vitamin K treatment (11, 13) . The current study expanded our knowledge of this putative role of vitamin K because our panel consisted of 14 biomarkers of inflammation, many of which have not been previously studied with respect to vitamin K. In contrast, our findings in this community sample did not support in vitro data which suggest that treatment with different forms of vitamin D may reduce production of inflammatory cytokines (35, 36) . However, we acknowledge that in in vitro studies, the active vitamin D metabolite (calcitriol) was more effective in influencing cytokine production, while in vivo 25-hydroxyvitamin D was used as the estimate of vitamin D status, since circulating concentrations of calcitriol are tightly controlled. Most studies in which a beneficial effect of vitamin D on inflammatory cytokines was reported were based on persons diagnosed with chronic diseases (19, 20, 37) . The Framingham Offspring Study is a study of a generally healthier, older cohort. Our results are similar to those of a single study by Gannage-Yared et al. (21) , who reported that supplementation with 25-hydroxyvitamin D did not influence concentrations of circulating cytokines in a small sample (n ¼ 47) of healthy postmenopausal women.
The mechanisms by which vitamin K influences biomarkers of inflammation are not known, although there is some suggestion that vitamin K suppresses inflammation by decreasing the expression of genes for individual cytokines, such as interleukin-6 and osteoprotegerin (13, 38) . Interleukin-6 and osteoprotegerin were the two markers that were inversely associated with both plasma phylloquinone concentration and phylloquinone intake in our study. Vitamin K, interleukin-6, and osteoprotegerin are all implicated in bone resorption and the regulation of vascular calcification (39) (40) (41) . Lower osteoprotegerin concentrations in skeletal and vascular tissue are associated with an increase in bone resorption and vascular calcification (42) , whereas patients with osteoporosis and cardiovascular disease are reported to have increased concentrations of circulating osteoprotegerin (43, 44) . Schoppet et al. (45) have proposed that these observed increases in circulating osteoprotegerin concentrations in patients with skeletal and/or vascular pathology are an incomplete compensatory response to factors leading to increased bone resorption and/or atherosclerosis. It has been assumed that any role of vitamin K in bone or cardiovascular health is mediated through its action as a cofactor in the carboxylation of vitamin K-dependent proteins, including osteocalcin. Whereas we observed an association between phylloquinone intake and plasma concentrations and overall inflammation, there was no association between percentage of undercarboxylated osteocalcin and overall inflammation. Percentage of undercarboxylated osteocalcin is used as a measure of the amount of vitamin K available for carboxylation in extrahepatic tissues. It is possible that vitamin K modulates inflammation by a mechanism that does not involve its role in c-carboxylation. The in vitro studies suggest a direct effect of vitamin K on gene expression that is not related to carboxylation of vitamin K-dependent proteins. Further, it has been shown that vitamin K has a protective effect against oxidative stress that is independent of carboxylation, which may be an alternative antiinflammatory mechanism associated with vitamin K (46) . The variation in biochemical measures of vitamin K status is determined by both dietary and nondietary factors (M. K. S., unpublished data), which may explain why the significance of associations of biochemical measures of vitamin K status and phylloquinone intake with individual markers of inflammation was not always consistent.
Calcitriol has been postulated to regulate immune function through the nuclear vitamin D receptor, which is expressed by most cells of the immune system. In vivo, the reported immunoregulatory effects of active vitamin D occur at very high concentrations (18) . Since the conversion of 25-hydroxyvitamin D to calcitriol is tightly regulated and the range of circulating calcitriol concentrations is narrow in the absence of chronic disease (47) , the reported effects of vitamin D on inflammation may not have been detected by our measures of vitamin D status in this community sample of healthy persons, similarly to the findings of GannageYared et al. (21) . Vitamin D status, as measured by plasma 25-hydroxyvitamin D, was inversely associated with urinary isoprostane concentration, a measure of oxidative stress. This inverse association is in general agreement with the findings of Lin et al. (48) , who reported a protective role of vitamin D in reducing oxidative stress by acting to terminate the lipid peroxidation chain reaction.
Strengths and limitations
There are several limitations to this study. Importantly, we tested associations between multiple biomarkers of inflammation and measures of vitamin K and D status, and we cannot discount the possibility that significant associations may have been due to chance because of multiple testing. We acknowledge that the measurement of some of the vitamin concentrations at examination 6 (49 percent), approximately 3 years prior to the measurement of inflammatory markers at examination 7, may have led to some misclassification; however, we did not observe significant effect modification by examination. The cross-sectional study design precluded causal inferences in interpreting our results. Although we modeled the relation of vitamins to inflammatory markers (dependent variables), we acknowledge that inflammatory markers may influence vitamin concentrations, or both may be related via other unmeasured intermediate factors.
Finally, although the associations were statistically significant, the clinical significance of the very modest changes we observed is uncertain. Many of the statistically significant associations would not have survived a strict Bonferroni correction, and our findings need to be replicated in other cohorts.
Balanced against these limitations are the novelty of the analyses and the routine ascertainment of vitamins, inflammatory biomarkers, and covariates in a community-based sample of men and women.
Clinical and research implications
Our findings provide one potential alternative mechanism for a putative protective effect of vitamin K in the progression of cardiovascular disease and osteoporosis, since both diseases are characterized by inflammation. Limited in vitro data support the inverse association between vitamin K and interleukin-6, and this may influence the association between vitamin K and other cytokines, such as osteoprotegerin. Further research to better elucidate mechanisms underlying the associations between vitamin K and inflammatory cytokines is warranted.
